Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 14/20 | 0.43 |
| ▸ | UBE2M | P61081 | 11/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365306 | 0.93 | POLB (0.44) | POLBRAB9ADCUN1D1UBE2MMCHR1 | |
| SCHEMBL19365722 | 0.92 | POLB (0.41) | POLBRAB9ADCUN1D1UBE2MMCHR1 | |
| SCHEMBL19365636 | 0.86 | POLB (0.46) | POLBRAB9ADCUN1D1UBE2MMCHR1 | |
| SCHEMBL19365519 | 0.86 | POLB (0.46) | POLBRAB9ADCUN1D1UBE2MMCHR1 | |
| SCHEMBL19670560 | 0.86 | POLB (0.47) | POLBRAB9AMCHR1RXFP1 | |
| SCHEMBL19365835 | 0.85 | CNR2 (0.53) | DCUN1D1UBE2M | |
| SCHEMBL19365866 | 0.85 | POLB (0.38) | POLBRAB9ADCUN1D1UBE2M | |
| SCHEMBL19706296 | 0.84 | POLB (0.39) | POLBRAB9ADCUN1D1UBE2MMCHR1 | |
| SCHEMBL19706120 | 0.84 | POLB (0.45) | POLBRAB9ADCUN1D1UBE2MMCHR1 | |
| SCHEMBL19670603 | 0.84 | POLB (0.43) | POLBRAB9ADCUN1D1UBE2MMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | POLB 961/4885RAB9A 1471/4885DCUN1D1 1730/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | POLB 961/4885RAB9A 1471/4885DCUN1D1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.